Enzyme News: Breaking Enzyme News, Comments and Articles. - Page: 5

Research Corporation Technologies and BioGrammatics Announce Partnership, Launch of the Pichia pastoris GlycoSwitch® Expression System

Research Corporation Technologies (RCT) and BioGrammatics, Inc. announced today their partnership to commercialize and distribute Pichia GlycoSwitch® – a new expression system to modify the glycosylation of recombinant proteins in the yeast Pichia pastoris. Pichia GlycoSwitch® adds to the advantages of using Pichia pastoris as a host for the production...

Alcresta Announces Board Appointments, Strengthening Team as Company Prepares for Nutritional Product Commercialization

Nutritional Industry Veteran Steve Dubin Appointed to Board of Directors; Gaetan Crucke and Chris Bleck Join Product Advisory Board Alcresta™, a science-driven company developing innovative enzyme-based nutritional products for adults, infants, and patients battling acute conditions or chronic diseases, today announced the appointment of Steve Dubin,...

Plasmin Delivered with Ultrasound Bubble-Busting Technology More Effective Busting Clots Than TPA

A new study has revealed that when delivered with the use of ultrasound, the natural enzyme plasmin is more effective...

VitaMedica ABCs of Recovery Support Simplifies Recovery after Plastic Surgery

VitaMedica launches a new tool to help patients choose the right nutritional product to speed recovery after plastic surgery. Patients can combine products to help with bruising, swelling and wound repair. Manhattan Beach, CA (PRWEB) June 04, 2013 VitaMedica introduces the ABCs of Recovery Support, a tool that guides patients in finding nutritional solutions to speed plastic surgery recovery time...

When DNA is out of place

When DNA that turns up in the wrong place in mammalian cells, the innate immune system reacts by secreting interferons. The structure and mode of action of the enzyme that mediates this response have now been elucidated.

KemPharm's KP201 Featured at the International Conference on Opioids

NORTH LIBERTY, Iowa, June 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that that its Vice President of Research, Sven Guenther, Ph.D., will present a poster on the Company's novel pain drug candidate, KP201, at the International Conference on Opioids (ICOO) in...

National Psoriasis Foundation awards six research grants worth $450,000 to scientists studying psoriasis and psoriatic arthritis

PORTLAND, Ore., June 4, 2013 /PRNewswire-USNewswire/ -- Six of the top scientists studying psoriasis—the most common autoimmune disease in the country, affecting 7.5 million Americans—and psoriatic arthritis, an inflammatory joint and tendon disease affecting up to 30 percent of people with psoriasis, received National Psoriasis Foundation (NPF) research grants totaling $450,000 for pr...

OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria

STOCKHOLM, June 4, 2013 /PRNewswire/ -- OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company's patent estate for this unmet medical need. "We are continuously working to further stren...

Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency

Human embryonic stem cells contain 5-hydroxymethylcytosine (5hmC) generated by the TET enzyme. Jin and colleagues show that TET1 increases 5hmC levels during reprogramming to human inducible pluripotent stem cells, and although this change is critica...

News From The Journal Of Clinical Investigation: June 3, 2013

A potential gene therapy for Mucopolysaccharidosis Type IIIA Mucopolysaccharidosis Type IIIA (MPSIIIA) is a metabolic disorder in which the body is missing an enzyme that is required to break down long chains of sugars known as glycosaminoglycans. Ov...

Innate immunity

(Ludwig-Maximilians-Universität München) When DNA turns up in the wrong place in mammalian cells, the innate immune system reacts by secreting interferons. The structure and mode of action of the enzyme that mediates this response have now been elu...

A potential gene therapy for Mucopolysaccharidosis Type IIIA

Mucopolysaccharidosis Type IIIA (MPSIIIA) is a metabolic disorder in which the body is missing an enzyme that is required to break down long chains of sugars known as glycosaminoglycans. Over time, the glycosaminoglycans collect in the body and cause...

Simon & Luke Files First Hepatitis A Lawsuit Against Townsend Farms and Costco Corporation, along with San Diego Co-Counsel Gomez Iagmin

SAN DIEGO, June 3, 2013 /PRNewswire/ -- Today the Houston-based food safety law firm of Simon & Luke, with co-counsel Gomez & Iagmin, filed the first lawsuit stemming from a multi-state Hepatitis A outbreak linked to consumption of a frozen berry mix manufactured by Oregon-based Townsend Farms and sold at Costco stores.   The lawsuit was filed against Townsend Farms an...

Research in Biberach – does the bioeconomy have a purple future?

What should be done with carbon dioxide? Following attempts to capture and deposit CO2 in places where it will not enter the atmosphere, the greenhouse gas is transforming from climate killer to raw material that can be used to produce valuable goods. Chemical processes require a great deal of energy to turn this inert gas into fuel, cement and plastics. Energy suppliers are also testing the feasi...

Edison Investment - Sygnis Pharma - Initiation of coverage - Life of phi

Sygnis develops molecular biology chemistry products targeted at the fast-growing DNA analysis and sequencing markets. The core IP is a range of engineered DNA polymerase enzymes, a specialist area where it has leading scientific expertise. The lead product, QualiPhi, has superior activity to the currently marketed phi29 enzyme (global market size: $50m). It is licensed for amplification of DNA...

Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer

SAN DIEGO, June 3, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer. The full data will be presented today at the 2013 American Society of Clinic...

Study Brings Artificial Livers One Step Closer To Reality

redOrbit staff & Wire Reports – Your Universe Online While the liver’s ability to regenerate itself has yet to be successfully harnessed to create artificial liver tissue for use in transplants, a team of researchers believe they are a step closer to overcoming the obstacles keeping this medical breakthrough from becoming a reality. Ordinarily, mature liver cells (also known as hepatocy...

Cyteir: Stopping shape-shifters

Cyteir is developing small molecule inhibitors of RAD51, a DNA repair enzyme used by many chronic lymphocytic leukemias.

In Mouse Models, New Agent Inhibits HCV Replication

Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of Korea and his collaborators have developed agents tha...

The lycopene enriched transgenic pineapple from Del Monte

At the PackerGenetically modified pineapple grown in Costa Rico by Del Monte Fresh Produce Co. Inc. gained the approval of the U.S. Department of Agriculture earlier this year.However, according to a statement from Del Monte officials April 26, the new pineapple variety — dubbed Rosé — is “in a testing phase.”“The USDA’s decision does not mean that Rosé is in commercial distribution;...

Expression and efficient secretion of a functional chitinase from Chromobacterium violaceum in Escherichia coli

Background: Chromobacterium violaceum is a free-living beta-proteobacterium found in tropical and subtropical regions. The genomic sequencing of C. violaceum ATCC 12472 has revealed many genes that underpin its adaptability to diverse ecosystems. Mor...

Incyte Presents Final Results from a Phase I Trial of INCB024360, a Novel Oral Immunotherapy, at ASCO

Data demonstrate that INCB024360 achieves greater than 90 percent inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents Incyte Corporation (...

Voices Against Brain Cancer Comments on New Potential Development in Brain Cancer Treatment

Voices Against Brain Cancer comments on a potential new target that gives promise for treating glioblastomas. New York, NY (PRWEB) June 01, 2013 On June 1, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a possible new target that may enhance brain cancer treatment. According to a Futurity.org article, researchers are working on targeting...

Synageva BioPharma™ Announces Presentations and a Satellite Symposium at the National Lipid Association Meeting

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association (NLA) annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013...

Roswell Park Cancer Institute, Jasco Pharmaceuticals Join Forces to Advance Drug Research

Organizations partner on preclinical testing of agent that has shown promise against solid tumors, blood cancers A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute (RPCI) and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacolog